Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Interest Expenses (2025)

KalVista Pharmaceuticals' Interest Expenses history spans 3 years, with the latest figure at $88000.0 for Q1 2016.

  • On a quarterly basis, Interest Expenses fell 89.47% to $88000.0 in Q1 2016 year-over-year; TTM through Jan 2017 was $88000.0, a N/A change, with the full-year FY2025 number at $5.8 million, changed N/A from a year prior.
  • Interest Expenses hit $88000.0 in Q1 2016 for KalVista Pharmaceuticals, roughly flat from $88000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for KALV hit a ceiling of $836000.0 in Q1 2015 and a floor of $80000.0 in Q1 2014.
  • Historically, Interest Expenses has averaged $262000.0 across 3 years, with a median of $95000.0 in 2015.
  • Biggest five-year swings in Interest Expenses: soared 945.0% in 2015 and later tumbled 89.47% in 2016.
  • Tracing KALV's Interest Expenses over 3 years: stood at $562000.0 in 2014, then plummeted by 84.34% to $88000.0 in 2015, then changed by 0.0% to $88000.0 in 2016.
  • Business Quant data shows Interest Expenses for KALV at $88000.0 in Q1 2016, $88000.0 in Q4 2015, and $95000.0 in Q3 2015.